© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
September 21, 2021
Relatlimab is the first LAG-3-blocking antibody to demonstrate a clinical benefit for patients with melanoma in phase 3 data.
Phase 3 trial results show that the drug reduced the risk of death or reoccurrence by 35% for individuals with high-risk disease compared with the placebo.
September 16, 2021
Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.
August 09, 2021
BCC is the most common form of skin cancer and is typically treated with surgical excision. However, excision can be a costly and burdensome treatment, especially for patients with multiple BCC lesions, according to the study.
August 04, 2021
The FDA has previously granted Orphan Drug designation to nemvaleukin for the treatment of mucosal melanoma.
July 28, 2021
AQP-modulating agent discovery has proved challenging, but many powerful AQP3 permeating molecules have been identified.
July 23, 2021
The FDA has granted Orphan Drug Designation (ODD) to alrizomadlin (APG-115, Ascentage Pharma) for the treatment of stage IIB-IV melanoma.
July 19, 2021
Many individuals underestimate the importance of protecting their skin from the sun.
July 13, 2021
Patients may consult with their pharmacist regarding appropriate protection methods and treatment options available for common summer skin ailments.
July 08, 2021
A recent study proved community pharmacies are model settings for skin cancer prevention education in rural communities with insufficient access to health care services.